<div id="readability-page-1"><div><ul> <li>Bruker Corporation recently reported a third quarter net loss of US$62.4 million and a 0.5% year-over-year decrease in sales, alongside a US$96.5 million goodwill impairment charge and a lowered financial outlook for fiscal 2025.</li> <li>Despite ongoing challenges, Bruker’s Board approved quarterly dividends for both common and preferred shareholders, highlighting a commitment to shareholder returns amid financial headwinds.</li> <li>We'll explore how the lowered financial outlook and substantial goodwill impairment may shift the investment narrative for Bruker going forward.</li> </ul><p>Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.</p><h2>Bruker Investment Narrative Recap</h2><p> To be a Bruker shareholder today, you need confidence in a multi-year recovery of global research and biopharma funding, and trust that the company’s profitability plan can overcome short-term headwinds. The latest news, notably the US$96.5 million goodwill impairment and lowered 2025 outlook, compounds pressure on organic revenue, the single most important near-term catalyst for Bruker, and intensifies the risk that ongoing order softness could further suppress top-line growth in a challenged funding climate. While these developments are significant, they don’t fundamentally shift Bruker’s biggest obstacle: depressed recurring revenue tied to cautious global R&amp;D spending. </p> <p> Among recent announcements, Bruker’s decision to maintain both common and preferred dividends stands out. Sustaining its quarterly dividend at US$0.05 per share, despite reporting losses and cutting guidance, underscores management’s commitment to rewarding shareholders even as macroeconomic and industry-specific risks cloud the revenue recovery story. </p> <p> Yet, in contrast to dividend stability, investors should be aware that persistent pressure on core order flow could challenge... </p> <p>Read the full narrative on Bruker (it's free!)</p><p>Bruker's narrative projects $3.8 billion revenue and $404.1 million earnings by 2028. This requires 3.2% yearly revenue growth and a $324.5 million earnings increase from current earnings of $79.6 million.</p><p>Uncover how Bruker's forecasts yield a $47.82 fair value, a 15% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/89bd5e8f-7b26-4c2f-a710-9970a0d54778/chart/community-fair-value?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/89bd5e8f-7b26-4c2f-a710-9970a0d54778/chart/community-fair-value"/><figcaption>BRKR Community Fair Values as at Nov 2025</figcaption></figure> <p> Simply Wall St Community members provided five independent fair value estimates for Bruker, ranging from US$31.30 to US$75.00 per share. With global research funding uncertainties posing the most substantial risk, consider how your view compares with these diverse opinions. </p><p>Explore 5 other fair value estimates on Bruker - why the stock might be worth as much as 80% more than the current price!</p><h2>Build Your Own Bruker Narrative</h2><p>Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.</p><ul><li>A great starting point for your Bruker research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.</li><li>Our free Bruker research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bruker's overall financial health at a glance.</li></ul><h2>Curious About Other Options?</h2><p>Our daily scans reveal stocks with breakout potential. Don't miss this chance:</p><ul><li>Outshine the giants: these 25 early-stage AI stocks could fund your retirement.</li><li>AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.</li><li>The latest GPUs need a type of rare earth metal called Terbium and there are only 37 companies in the world exploring or producing it. Find the list for free.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p></div></div>

BRKR

<p>Bruker Corporation reported a Q3 net loss of $62.4 million, a 0.5% sales decrease, and a $96.5 million goodwill impairment, lowering its 2025 financial outlook. Despite challenges, Bruker maintains dividends, showing commitment to shareholders. The investment narrative highlights risks from global R&D funding pressures and organic revenue challenges. Bruker's projected revenue and earnings growth by 2028 suggest a fair value of $47.82, offering a 15% upside. Diverse fair value estimates range from $31.30 to $75.00 per share, reflecting uncertainties in research funding.</p>

Is Bruker's Goodwill Impairment and Lowered Outlook Reshaping the Investment Case for BRKR?